Catheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line
Catheter Precision (NYSE/American: VTAK) has received its first US patent allowance for the LockeT surgical closure device, designed for orthoscopic entry wounds. This adds to the company's existing international patents for LockeT in China, Europe, and the United Kingdom.
The company expects to receive the CE mark for LockeT in the current quarter, which will enable revenue generation in Europe. The product has been well-received since its US rollout in late last year, offering improved outcomes while reducing procedure costs in international markets.
Catheter Precision (NYSE/American: VTAK) ha ricevuto la sua prima concessione di brevetto negli Stati Uniti per il dispositivo di chiusura chirurgica LockeT, progettato per ferite da accesso ortoscopico. Questo si aggiunge ai brevetti internazionali esistenti per LockeT in Cina, Europa e Regno Unito.
L'azienda prevede di ottenere il marchio CE per LockeT nel trimestre attuale, il che consentirà la generazione di entrate in Europa. Il prodotto è stato ben accolto sin dal suo lancio negli Stati Uniti alla fine dello scorso anno, offrendo risultati migliorati e riducendo i costi delle procedure nei mercati internazionali.
Catheter Precision (NYSE/American: VTAK) ha recibido su primera concesión de patente en EE.UU. para el dispositivo de cierre quirúrgico LockeT, diseñado para heridas de entrada ortoscópica. Esto se suma a las patentes internacionales existentes de LockeT en China, Europa y el Reino Unido.
La compañía espera recibir el marcado CE para LockeT en el trimestre actual, lo que permitirá la generación de ingresos en Europa. El producto ha sido bien recibido desde su lanzamiento en EE.UU. a finales del año pasado, ofreciendo mejores resultados y reduciendo los costos de los procedimientos en los mercados internacionales.
Catheter Precision (NYSE/American: VTAK)는 정형외과적 접근 상처를 위해 설계된 외과적 폐쇄 장치 LockeT에 대해 미국에서 첫 번째 특허 허가를 받았습니다. 이는 중국, 유럽 및 영국에서 LockeT에 대한 기존의 국제 특허에 추가됩니다.
회사는 현재 분기에 LockeT에 대한 CE 마크를 받을 것으로 예상하고 있으며, 이는 유럽에서의 수익 창출을 가능하게 합니다. 이 제품은 지난해 말 미국에서 출시된 이후로 좋은 반응을 얻었으며, 국제 시장에서 절차 비용을 줄이면서 개선된 결과를 제공합니다.
Catheter Precision (NYSE/American: VTAK) a reçu sa première autorisation de brevet aux États-Unis pour le dispositif de fermeture chirurgicale LockeT, conçu pour les blessures d'entrée orthoscopiques. Cela s'ajoute aux brevets internationaux existants pour LockeT en Chine, en Europe et au Royaume-Uni.
La société s'attend à obtenir le marquage CE pour LockeT au cours du trimestre actuel, ce qui permettra de générer des revenus en Europe. Le produit a été bien accueilli depuis son lancement aux États-Unis à la fin de l'année dernière, offrant de meilleurs résultats tout en réduisant les coûts des procédures sur les marchés internationaux.
Catheter Precision (NYSE/American: VTAK) hat die erste US-Patenterlaubnis für das chirurgische Verschlussgerät LockeT erhalten, das für orthoskopische Zugangswunden entwickelt wurde. Dies ergänzt die bestehenden internationalen Patente für LockeT in China, Europa und dem Vereinigten Königreich.
Das Unternehmen erwartet, im aktuellen Quartal die CE-Kennzeichnung für LockeT zu erhalten, was die Generierung von Einnahmen in Europa ermöglichen wird. Das Produkt wurde seit seiner Einführung in den USA Ende letzten Jahres gut angenommen und bietet verbesserte Ergebnisse bei gleichzeitiger Senkung der Verfahrenskosten auf internationalen Märkten.
- First US patent allowance secured for LockeT surgical closure device
- Existing international patents in China, Europe, and UK strengthen IP portfolio
- CE mark approval expected in current quarter enabling European market entry
- Positive initial market reception following US rollout
- None.
Fort Mill, S.C., April 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received a notice of allowance from the US Patent Office of its first patent in the US for its LockeT product, filed in December 2022, for its design of a surgical closure device for orthoscopic entry wounds.
David Jenkins, CEO of Catheter Precision, commented, “This first US patent for LockeT joins our other issued international LockeT patents that have now been issued in China, Europe, and the United Kingdom. Intellectual property protection within this large market is quite meaningful to us as we begin discussions for distribution in China and also Europe. We expect to receive the CE mark for LockeT in this quarter which clears the way to begin revenue creation in Europe. In markets outside of the United States, hospitals are also looking for new products that provide great outcomes while reducing cost per procedure. Our LockeT fits these parameters well. In the US, we began our roll out late last year, and we are quite pleased with the reception so far.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
FAQ
When did Catheter Precision receive its first US patent allowance for LockeT (VTAK)?
In which countries does Catheter Precision (VTAK) hold patents for the LockeT device?
When is Catheter Precision (VTAK) expecting to receive the CE mark for LockeT?
When did Catheter Precision (VTAK) begin rolling out LockeT in the US market?
